Literature DB >> 19504470

Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions.

Bryan Maloney1, Yuan-Wen Ge, Ronald C Petersen, John Hardy, Jack T Rogers, Jordi Pérez-Tur, Debomoy K Lahiri.   

Abstract

Variations in levels of apolipoprotein E (ApoE) have been tied to the risk and progression of Alzheimer's disease (AD). Our group has previously compared and contrasted the promoters of the mouse and human ApoE gene (APOE) promoter sequences and found notable similarities and significant differences that suggest the importance of the APOE promoter's role in the human disease. We examine here three specific single-nucleotide polymorphisms within the human APOE promoter region, specifically at -491 (A/T), -427 (T/C), and at -219 (G/T) upstream from the +1 transcription start site. The -219 and -491 polymorphic variations have significant association with instance of AD, and -491AA has significant risk even when stratified for the APOEepsilon4 allele. We also show significant effects on reporter gene expression in neuronal cell cultures, and, notably, these effects are modified by species origin of the cells. The -491 and -219 polymorphisms may have an interactive effect in addition to any independent activity. DNA-protein interactions differ between each polymorphic state. We propose SP1 and GATA as candidates for regulatory control of the -491 and -219 polymorphic sites. This work's significance lies in drawing connection among APOE promoter polymorphisms' associations with AD to functional promoter activity differences and specific changes in DNA-protein interactions in cell culture-based assays. Taken together, these results suggest that APOE expression levels are a risk factor for AD irrespective of APOEepsilon4 allele status. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19504470      PMCID: PMC5875733          DOI: 10.1002/ajmg.b.30973

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  57 in total

1.  Efficient DNA transfection in neuronal and astrocytic cell lines.

Authors:  C Ghosh; W Song; D K Lahiri
Journal:  Mol Biol Rep       Date:  2000-06       Impact factor: 2.316

2.  Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Authors:  J-C Lambert; D Mann; F Richard; J Tian; J Shi; U Thaker; S Merrot; J Harris; B Frigard; T Iwatsubo; C Lendon; P Amouyel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice.

Authors:  Remi Dosunmu; Jinfang Wu; Lina Adwan; Bryan Maloney; Md Riyaz Basha; Christopher A McPherson; G Jean Harry; Deborah C Rice; Nasser H Zawia; Debomoy K Lahiri
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 4.  Functional characterization of amyloid beta precursor protein regulatory elements: rationale for the identification of genetic polymorphism.

Authors:  Debomoy K Lahiri
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

Review 5.  How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD.

Authors:  Debomoy K Lahiri; Bryan Maloney; Md Riyaz Basha; Yuan Wen Ge; Nasser H Zawia
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

6.  NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells.

Authors:  Yansheng Du; Xianming Chen; Xing Wei; Kelly R Bales; David T Berg; Steven M Paul; Martin R Farlow; Bryan Maloney; Yuan-Wen Ge; Debomoy K Lahiri
Journal:  Brain Res Mol Brain Res       Date:  2005-05-20

7.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.

Authors:  M J Bullido; M J Artiga; M Recuero; I Sastre; M A García; J Aldudo; C Lendon; S W Han; J C Morris; A Frank; J Vázquez; A Goate; F Valdivieso
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

Review 8.  Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors.

Authors:  Kumar Sambamurti; Ann-Charlotte Granholm; Mark S Kindy; Narayan R Bhat; Nigel H Greig; Debomoy K Lahiri; Jacobo E Mintzer
Journal:  Curr Drug Targets       Date:  2004-08       Impact factor: 3.465

9.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

10.  APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.

Authors:  S M Laws; R M Clarnette; K Taddei; G Martins; A Paton; J Hallmayer; O P Almeida; D M Groth; S E Gandy; H Förstl; R N Martins
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

View more
  24 in total

1.  Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinson's Disease: A Study from Eastern India.

Authors:  Prosenjit Pal; Tamal Sadhukhan; Subhadip Chakraborty; Sriparna Sadhukhan; Arindam Biswas; Shyamal K Das; Kunal Ray; Jharna Ray
Journal:  Neuromolecular Med       Date:  2019-05-28       Impact factor: 3.843

2.  Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease.

Authors:  Bryan Maloney; Debomoy K Lahiri
Journal:  Gene       Date:  2012-01-30       Impact factor: 3.688

3.  The effects of an APOE promoter polymorphism on human cortical morphology during nondemented aging.

Authors:  Yaojing Chen; Peng Li; Bin Gu; Zhen Liu; Xin Li; Alan C Evans; Gaolang Gong; Zhanjun Zhang
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

4.  The Transcriptional Regulatory Properties of Amyloid Beta 1-42 may Include Regulation of Genes Related to Neurodegeneration.

Authors:  Duygu Gezen-Ak; İrem L Atasoy; Esin Candaş; Merve Alaylıoğlu; Erdinç Dursun
Journal:  Neuromolecular Med       Date:  2018-06-12       Impact factor: 3.843

Review 5.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

6.  Gene × environment interaction by a longitudinal epigenome-wide association study (LEWAS) overcomes limitations of genome-wide association study (GWAS).

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Epigenomics       Date:  2012-12       Impact factor: 4.778

7.  Gata5 deficiency causes airway constrictor hyperresponsiveness in mice.

Authors:  Bohao Chen; Tamson V Moore; Zhenping Li; Anne I Sperling; Chunling Zhang; Jorge Andrade; Alex Rodriguez; Neil Bahroos; Yong Huang; Edward E Morrisey; Peter J Gruber; Julian Solway
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

8.  Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype.

Authors:  Marilyn Albert; Anja Soldan; Rebecca Gottesman; Guy McKhann; Ned Sacktor; Leonie Farrington; Maura Grega; Raymond Turner; Yi Lu; Shanshan Li; Mei-Cheng Wang; Ola Selnes
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

Review 9.  Impact of apolipoprotein E on Alzheimer's disease.

Authors:  Paul S Hauser; Robert O Ryan
Journal:  Curr Alzheimer Res       Date:  2013-10       Impact factor: 3.498

10.  The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps.

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Exp Gerontol       Date:  2010-01-11       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.